o(6)-benzylguanine has been researched along with Neoplasms in 21 studies
O(6)-benzylguanine: a suicide inhibitor of O(6)-methylguanine-DNA methyltransferase activity
Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Temozolomide was administered orally, daily for 5 days starting at 28 mg/m(2) per day with escalations to 40, 55, 75 and 100 mg/m(2) per day with O(6)BG intravenously daily for 5 days at doses of 60, 90 or 120 mg/m(2) per day." | 2.74 | Pharmacokinetics of temozolomide administered in combination with O6-benzylguanine in children and adolescents with refractory solid tumors. ( Aikin, AA; Balis, FM; Cole, DE; Fox, E; Meany, HJ; Warren, KE, 2009) |
| "To report the results of the first pharmacokinetic study in pediatric patients of O(6)-benzylguanine (O(6)BG), which irreversibly inactivates the DNA repair protein alkylguanine-alkyltransferase, thus enhancing the cytotoxicity of nitrosoureas." | 2.71 | Pharmacokinetics of O(6)-benzylguanine in pediatric patients with central nervous system tumors: a pediatric oncology group study. ( Adams, D; Aleksic, A; Berg, S; Bernstein, M; Blaney, S; Neville, K; Thompson, P, 2004) |
| " The half-life of O6-Benzyl-8-oxoguanine increased with dose from 2." | 2.69 | O6-benzylguanine in humans: metabolic, pharmacokinetic, and pharmacodynamic findings. ( Dolan, ME; Fasanmade, AA; Paras, PR; Ratain, MJ; Roy, SK; Schilsky, RL, 1998) |
| "Early phase evaluation of anticancer drugs has traditionally used toxicity (usually hematological) rather than efficacy end points to establish appropriate dosing schedules." | 2.69 | O6-benzylguanine: a clinical trial establishing the biochemical modulatory dose in tumor tissue for alkyltransferase-directed DNA repair. ( Gerson, SL; Haaga, J; Hoppel, CL; Ingalls, ST; Liu, L; Majka, S; Pluda, JM; Spiro, TP; Willson, JK, 1999) |
| "Expression of MGMT in human cancers has been associated with resistance to therapies using alkylating agents." | 2.44 | S-alkylthiolation of O6-methylguanine-DNA-methyltransferase (MGMT) to sensitize cancer cells to anticancer therapy. ( Juillerat, A; Juillerat-Jeanneret, L, 2007) |
| " Extended dosing has met with early favourable results." | 2.43 | Exploiting the role of O6-methylguanine-DNA-methyltransferase (MGMT) in cancer therapy. ( Middleton, MR; Sabharwal, A, 2006) |
| "The one exception is those tumors lacking mismatch repair, which renders them resistant to methylating agents." | 2.41 | Clinical relevance of MGMT in the treatment of cancer. ( Gerson, SL, 2002) |
| "Cancer cells can be killed by photosensitizing agents that induce toxic effects when exposed to nonhazardous light, but this also causes significant damage to surrounding healthy cells." | 1.37 | SNAP-tag technology mediates site specific conjugation of antibody fragments with a photosensitizer and improves target specific phototoxicity in tumor cells. ( Barth, S; Hussain, AF; Kampmeier, F; Merk, HF; Tur, MK; von Felbert, V, 2011) |
| "In the setting of target-based anticancer drug development, it is critical to establish that the observed preclinical activity can be attributed to modulation of the intended target in early phase trials in human subjects." | 1.31 | Sequential tumor biopsies in early phase clinical trials of anticancer agents for pharmacodynamic evaluation. ( Berger, NA; Berger, SJ; Dowlati, A; Gerson, SL; Haaga, J; Liu, L; Remick, SC; Spiro, TP; Willson, JK, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (33.33) | 18.2507 |
| 2000's | 12 (57.14) | 29.6817 |
| 2010's | 2 (9.52) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Diamandis, P | 1 |
| Wildenhain, J | 1 |
| Clarke, ID | 1 |
| Sacher, AG | 1 |
| Graham, J | 1 |
| Bellows, DS | 1 |
| Ling, EK | 1 |
| Ward, RJ | 1 |
| Jamieson, LG | 1 |
| Tyers, M | 1 |
| Dirks, PB | 1 |
| Meany, HJ | 1 |
| Warren, KE | 2 |
| Fox, E | 2 |
| Cole, DE | 1 |
| Aikin, AA | 2 |
| Balis, FM | 2 |
| Robinson, C | 1 |
| Palomo, J | 1 |
| Vogelbaum, MA | 1 |
| Hussain, AF | 1 |
| Kampmeier, F | 1 |
| von Felbert, V | 1 |
| Merk, HF | 1 |
| Tur, MK | 1 |
| Barth, S | 1 |
| Dolan, ME | 5 |
| Posner, M | 1 |
| Karrison, T | 1 |
| Radosta, J | 1 |
| Steinberg, G | 1 |
| Bertucci, D | 2 |
| Vujasin, L | 1 |
| Ratain, MJ | 3 |
| Neville, K | 1 |
| Blaney, S | 1 |
| Bernstein, M | 1 |
| Thompson, P | 1 |
| Adams, D | 1 |
| Aleksic, A | 1 |
| Berg, S | 1 |
| Libucha, M | 1 |
| Widemann, BC | 1 |
| Packer, RJ | 1 |
| Ding, J | 1 |
| Miao, ZH | 1 |
| Meng, LH | 1 |
| Geng, MY | 1 |
| Sabharwal, A | 1 |
| Middleton, MR | 1 |
| Juillerat, A | 1 |
| Juillerat-Jeanneret, L | 1 |
| Gerson, SL | 5 |
| Willson, JK | 4 |
| Wedge, SR | 1 |
| Porteous, JK | 1 |
| Newlands, ES | 1 |
| Roy, SK | 1 |
| Fasanmade, AA | 1 |
| Paras, PR | 1 |
| Schilsky, RL | 2 |
| Pegg, AE | 1 |
| Kleibl, K | 1 |
| Margison, GP | 1 |
| Wu, MH | 1 |
| Lohrbach, KE | 1 |
| Olopade, OI | 1 |
| Kokkinakis, DM | 1 |
| Friedman, HS | 1 |
| Spiro, TP | 3 |
| Liu, L | 3 |
| Majka, S | 2 |
| Haaga, J | 3 |
| Hoppel, CL | 1 |
| Ingalls, ST | 1 |
| Pluda, JM | 1 |
| Ewesuedo, RB | 1 |
| Vogelzang, NJ | 1 |
| Mani, S | 1 |
| Wilson, LR | 1 |
| Qin, X | 1 |
| Schupp, J | 1 |
| Dowlati, A | 1 |
| Remick, SC | 1 |
| Berger, SJ | 1 |
| Berger, NA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase I Trial and Pharmacokinetic Study of Temozolomide and O6-Benzylguanine in Childhood Solid Tumors[NCT00020150] | Phase 1 | 0 participants | Interventional | 2000-06-30 | Completed | ||
| Dovitinib In 1st-Line Renal Cell Carcinoma, an Investigation Into Tumour GENe Status and Correlation With Efficacy - 1st Exploratory Study[NCT01791387] | Phase 2 | 30 participants (Anticipated) | Interventional | 2012-03-31 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
7 reviews available for o(6)-benzylguanine and Neoplasms
| Article | Year |
|---|---|
Emerging cancer therapeutic opportunities target DNA-repair systems.
Topics: Animals; Antineoplastic Agents; Ataxia Telangiectasia Mutated Proteins; Cell Cycle Proteins; DNA Dam | 2006 |
Exploiting the role of O6-methylguanine-DNA-methyltransferase (MGMT) in cancer therapy.
Topics: Animals; Antineoplastic Agents; Camptothecin; Clinical Trials as Topic; Dacarbazine; DNA Adducts; DN | 2006 |
S-alkylthiolation of O6-methylguanine-DNA-methyltransferase (MGMT) to sensitize cancer cells to anticancer therapy.
Topics: Antineoplastic Agents, Alkylating; Drug Resistance, Neoplasm; Enzyme Inhibitors; Guanine; Humans; Mu | 2007 |
O6-alkylguanine-DNA alkyltransferase. A target for the modulation of drug resistance.
Topics: Alkylating Agents; Biological Transport; Carmustine; Clinical Trials as Topic; DNA Damage; DNA Repai | 1995 |
O6-benzylguanine and its role in chemotherapy.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; DNA Repa | 1997 |
Increasing DNA repair capacity in bone marrow by gene transfer as a prospective tool in cancer therapy.
Topics: Alkylation; Amino Acid Sequence; Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; | 1998 |
Clinical relevance of MGMT in the treatment of cancer.
Topics: Antineoplastic Agents; DNA Adducts; DNA Repair; Drug Resistance, Neoplasm; Genetic Therapy; Guanine; | 2002 |
7 trials available for o(6)-benzylguanine and Neoplasms
| Article | Year |
|---|---|
Pharmacokinetics of temozolomide administered in combination with O6-benzylguanine in children and adolescents with refractory solid tumors.
Topics: Adolescent; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Ch | 2009 |
Determination of the optimal modulatory dose of O6-benzylguanine in patients with surgically resectable tumors.
Topics: Aged; Aged, 80 and over; Animals; Antineoplastic Agents; CHO Cells; Cricetinae; DNA Methylation; DNA | 2002 |
Pharmacokinetics of O(6)-benzylguanine in pediatric patients with central nervous system tumors: a pediatric oncology group study.
Topics: Adolescent; Adult; Antineoplastic Agents; Area Under Curve; Brain Neoplasms; Central Nervous System | 2004 |
Phase I study of O6-benzylguanine and temozolomide administered daily for 5 days to pediatric patients with solid tumors.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Dacarbaz | 2005 |
O6-benzylguanine in humans: metabolic, pharmacokinetic, and pharmacodynamic findings.
Topics: Alkyl and Aryl Transferases; Antineoplastic Agents; Guanine; Half-Life; Humans; Infusions, Intraveno | 1998 |
O6-benzylguanine: a clinical trial establishing the biochemical modulatory dose in tumor tissue for alkyltransferase-directed DNA repair.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Biopsy; Biotransformation; Breast Neoplasms; Carmust | 1999 |
Phase I clinical and pharmacological study of O6-benzylguanine followed by carmustine in patients with advanced cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Dose-Res | 2000 |
7 other studies available for o(6)-benzylguanine and Neoplasms
| Article | Year |
|---|---|
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutic | 2007 |
Thin layer chromatography-based assay of O6-methylguanine-DNA methyltransferase activity in tissue.
Topics: Cell Line, Tumor; Chromatography, Thin Layer; Fluorescent Dyes; Guanine; Humans; Neoplasms; O(6)-Met | 2010 |
SNAP-tag technology mediates site specific conjugation of antibody fragments with a photosensitizer and improves target specific phototoxicity in tumor cells.
Topics: Cell Line, Tumor; Chlorophyllides; Drug Delivery Systems; ErbB Receptors; Gene Expression; Guanine; | 2011 |
3-aminobenzamide and/or O6-benzylguanine evaluated as an adjuvant to temozolomide or BCNU treatment in cell lines of variable mismatch repair status and O6-alkylguanine-DNA alkyltransferase activity.
Topics: Antineoplastic Agents, Alkylating; Benzamides; Carmustine; Dacarbazine; DNA Repair; Drug Screening A | 1996 |
Lack of evidence for a polymorphism at codon 160 of human O6-alkylguanine-DNA alkyltransferase gene in normal tissue and cancer.
Topics: Animals; Antineoplastic Agents; Cattle; Codon; Drug Resistance, Neoplasm; Drug Screening Assays, Ant | 1999 |
Differential degradation rates of inactivated alkyltransferase in blood mononuclear cells and tumors of patients after treatment with O(6)-benzylguanine.
Topics: Biopsy; Blotting, Western; Enzyme Inhibitors; Guanine; Humans; Leukocytes, Mononuclear; Neoplasms; O | 2001 |
Sequential tumor biopsies in early phase clinical trials of anticancer agents for pharmacodynamic evaluation.
Topics: Animals; Antineoplastic Agents; Biopsy; Carmustine; Cisplatin; Clinical Trials, Phase I as Topic; Cl | 2001 |